Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. Dongliang Guan graduated from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2019. Under the supervision of Professor Wei Huang, he obtained a doctorate in medicinal chemistry. Subsequently, from August 2019 to November 2020, he joined the research group of Professor Tariq Rana at the University of California, San Diego as a postdoctoral fellow. From November 2020 to November 2022, he joined the research group of Chunyang Jin in the Center for Drug Discovery at RTI International to continue his postdoctoral training in medicinal chemistry. Since the end of December 2022, Dr. Guan has been appointed as a principal investigator and professor of medicinal chemistry in the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. Guan has long been engaged in the development of novel antibiotics. He has published over 20 scientific papers in Angew. Chem. Int. Ed., J. Med. Chem., and other high-impact scientific journals. Currently, his research group mainly focuses on the development of new drugs for the emergency treatment of high-risk drug-resistant pathogens driven by new structural modification strategies and new mechanisms. The novel glycopeptide antibiotic SM-V-61, in which he is a major participant, has already obtained a clinical approval and is currently in Phase I clinical study.

Education Experience：

09/01/2014 - 06/30/2019 Ph.D.in Medicinal Chemistry, Shanghai Institute of Materia Medica

09/01/2010 - 06/30/2014 B.S.in Pharmacy, Yantai University

Work Experience：

01/01/2024 - now Professor, Shanghai Institute of Materia Medica

12/15/2022 – 12/31/2023 Associate Professor, Shanghai Institute of Materia Medica

11/09/2020 - 11/08/2022 Postdoctoral Fellow, Center for Drug Discovery in RTI International

8/20/2019 - 11/08/2020 Postdoctoral Fellow, School of Medicine in University of California, San Diego

Research Directions

1. Synthetic Medicinal Chemistry of Novel Antibacterial Agents

2. Synthetic Medicinal Chemistry of Novel Antifungal Agents

Grants & Research Projects

2024-2026 Youth Fund of the National Natural Science Foundation of China

2025-2027 Youth Fund of the Shandong Natural Science Foundation

Achievements

We have developed glycosylation modification strategy, pyrophosphate-targeted modification strategy, sulfonium modification strategy and amine/guanidine modification strategy on glycopeptide antibiotics, which effectively overcome the corresponding bacterial antibiotic resistance. Moreover, we have thus obtained a candidate drug molecule SM-V-61, which has currently passed the IND application (November 2024) and is now in Phase I clinical study.

morefold

Social Titles

2024 Young Editorial Board Member, Chinese Journal of Antibiotics2024 Young Committee Member of the Antibiotics Professional Committee of Shanghai Pharmaceutical Association

morefold

Awards & Honors

2023 Shanghai Magnolia Young Talent

2023 Shanghai Pudong New Area Pearl Elite Talent

morefold

Pubilcations

Full Publication List

Selected Publications

1.Xiaolei Bian, Zhifu Chen, Fang Li, Yuanyuan Xie, Yi Li, Youhong Luo, Xiangman Zou, Hui Wang, Jingwen Zhang, Xiaowen Wang*Jinyong Zhang* Dongliang Guan*, Single Amine or Guanidine Modification on Norvancomycin and Vancomycin to Overcome Multidrug-Resistance through Augmented Lipid II Binding and Increased Membrane Activity, Journal of Medicinal Chemistry 2024, DOI: 10.1021/acs.jmedchem.4c02196.

2.Dongliang Guan*, Jiaxiang Liu, Feifei Chen, Jian Li, Xiaowen Wang, Weiwei Lu, Yanrui Suo, Feng Tang, Lefu Lan*, Xiaojie Lu*, and Wei Huang*, A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria. Journal of Medicinal Chemistry 2024, 67, 3778−3794.

3.Dongliang Guan*, Jian Li, Feifei Chen, Jiaqi Li, Xiaolei Bian, Yue Yu, Xinxin Feng*, Lefu Lan* and Wei Huang*, A facile and selective derivatization approach on kynurenine-NH2 in daptomycin, leading to the discovery of hexakynomycin to combat multidrug-resistant Gram-positive pathogens especially daptomycin-resistant bacteria. European Journal of Medicinal Chemistry 2023, 259, 115638.

4.Dongliang Guan*, Feifei Chen, Wei Shi, Lefu Lan* and Wei Huang*, Single Modification at the N-Terminus of Norvancomycin to Combat Drug-Resistant Gram-Positive Bacteria. ChemMedChem 2023, 18, e202200708.

5.Dongliang Guan, Md Toufiqur Rahman, Elaine A. Gay, Vineetha Vasukuttan, Kelly M. Mathews, Ann M. Decker, Alexander H. Williams, Chang-Guo Zhan, and Chunyang Jin*. Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure–Activity Relationship, and Molecular Modeling Studies. Journal of Medicinal Chemistry 2021, 64(24), 17866–17886.

6.Dongliang Guan, Feifei Chen, Yunguang Qiu, Bofeng Jiang, Likun Gong, Lefu Lan*, Wei Huang*. Sulfonium, an underestimated moiety for structural modification, alters antibacterial profile of vancomycin against multidrug-resistant bacteria. Angew. Chem., Int. Ed. 2019, 58 (20), 6678–6682.

morefold